Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06146517 · ClinicalTrials.gov registry record · NA
A Single-Arm, Virtual Clinical Trial to Evaluate the Effects of a Sleep Supporting Beverage and Two Coffee Substitute Products
A NA study of Anxiety and Sleep, sponsored by Clevr Blends.
- Completed
- Registry status
- NA
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT06146517: Completed NA study of Anxiety and Sleep, sponsored by Clevr Blends.
NCT06146517 is a NA study of Anxiety and Sleep that has completed, run by Clevr Blends. The registered enrollment target is 32 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06146517, a NA study of Anxiety and Sleep, has completed, sponsored by Clevr Blends.
- COMPLETED
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a virtual, single-arm clinical trial that will last 12 weeks. Participants will trial three different products, each for 4 weeks. Participants will trial Clevr Blends Sleeptime during weeks 1-4, Clevr Matcha for weeks 5-8, and Clevr Blends Chai for weeks 9-12. Participants will complete questionnaires at Baseline and Week 2, 4, 6, 8, 10, and 12. In addition to data will be collected from participants' sleep tracking devices at Baseline, Week 2, and Week 4.
Primary Outcome
All participants will wear a sleep tracking device (e.g. Fitbit, Whoop, Oura etc) to record their total time asleep each night.
Conditions Studied
Interventions
- OTHER Clevr Sleeptime
- OTHER Clevr Matcha
- OTHER Clevr Chai
Study Locations (1)
California
- Citruslabs - Santa Monica
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2023-08-31 |
| Est. Completion | 2024-01-22 |
| Phase | NA |
What the finished NCT06146517 record still lists
NCT06146517 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (93% lower).
The record links to 5 conditions, with Anxiety appearing as the primary indexed condition, and to 3 interventions - of which Clevr Sleeptime is the first listed.
NCT06146517 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06146517 about?
NCT06146517 is a clinical study titled "A Single-Arm, Virtual Clinical Trial to Evaluate the Effects of a Sleep Supporting Beverage and Two Coffee Substitute Products". This is a virtual, single-arm clinical trial that will last 12 weeks. Participants will trial three different products, each for 4 weeks. Participants will trial Clevr Blends Sleeptime during weeks 1-4, Clevr Matcha for weeks 5-8, and Clevr Blends Chai for weeks 9-12. Participants will complete ques...
What is the current status of trial NCT06146517?
This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2023-08-31. Estimated completion is 2024-01-22.
What conditions does trial NCT06146517 study?
This clinical trial studies the following conditions: Anxiety, Sleep, Mood, Caffeine Withdrawal, Productivity.
What interventions are being tested in trial NCT06146517?
The interventions under investigation include: Clevr Sleeptime (OTHER), Clevr Matcha (OTHER), Clevr Chai (OTHER).
Who is sponsoring clinical trial NCT06146517?
This trial is sponsored by Clevr Blends, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06146517 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06146517's enrollment target sits among peer trials
32 297th of 364 higher than 67 of 364 other Anxiety trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anxiety trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Focused Ultrasound for the Complex Patient
RECRUITING · NA
-
Digital Intervention for Physical Activity
RECRUITING · NA
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
Brief Interventions for Coping with Distress
RECRUITING · NA
-
Personalized Feedback Intervention for Latinx Drinkers With Anxiety
RECRUITING · NA
-
Pilot Effectiveness Trial of an ACT Self-help Workbook Tailored Specifically for Prisons
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI